Episode 16 (April 5, 2024): This week, the GEN editors discussed deep proteome profiling of home-sampled dried blood spots to assess the effects of SARS-CoV-2 in mildly symptomatic or asymptomatic, rapid liquid nitrogen treatment for converting tumor cells into carriers for gene editing tools that target cancer in vivo, Verve Therapeutics’ pausing of a clinical trial due to a serious adverse event,  Iambic Therapeutics’ advancement of its first AI-designed candidate into the clinic, and the launch of Diagonal Therapeutics to find agonist antibodies for heteromeric receptor complexes.

Featuring Uduak Thomas (Senior Editor, GEN), Alex Philippidis (Senior Business Editor, GEN) Jonathan Grinstein, PhD, (Senior Editor, GEN), and moderated by Corinna Singleman, PhD, (Managing Editor, GEN and IPM)

Listed below are key references to the GEN stories, media, and other items discussed in this episode of Touching Base:

The State of Omics 2024 Registration
GEN Summit

COVID-19 Infections Detected in Dried Blood Spots via At-Home Proteomic Profiling
By GEN, April 2, 2024.

CRISPR-Cas9 Targets Lung Cancer Using Cryo-Shocked Tumor Cells
By GEN, March 31, 2024.

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
By Alex Philippidis, GEN, April 3, 2024.

Archimedes’ Box: Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies
By Jonathan D. Grinstein, PhD, GEN Edge, April 3, 2024.

Previous articleFlipping the Script: Atomwise AI Platform Presents an Alternative to High Throughput Screening
Next articleBittersweet Symphony: Verve’s Pause on VERVE-101 Narrows LNP-Delivery Strategy